OMDA

Omada Health, Inc. (OMDA) - Q1 2026 Filing Summary

Business Context and Reporting Period

This Quarterly Report on Form 10-Q covers the period ended March 31, 2026. Omada Health, Inc. is a digital health company offering virtual care programs for cardiometabolic conditions (prediabetes, diabetes, hypertension), musculoskeletal (MSK) conditions, and behavioral health. The company operates as a single reporting segment and is classified as an emerging growth company. As of March 31, 2026, the company reported over 1.025 million total members, surpassing the one-million member milestone for the first time.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased by 42% ($23.1 million) year-over-year. Services revenue grew 41% and hardware revenue grew 55%, driven primarily by a 51% increase in total members.
• Margin Expansion: Gross margin expanded by 4.3 percentage points to 62.4%, attributed to Care Team efficiency initiatives and the expanded use of supporting technologies.
• Loss Reduction: Net loss decreased significantly by 69% to $3.0 million, compared to $9.4 million in Q1 2025. Operating loss narrowed to $4.8 million from $8.4 million.
• Liquidity Position: Cash balances increased substantially to $211.8 million, bolstered by $151.6 million in net proceeds from the company's IPO completed in June 2025. The company used IPO proceeds to fully repay its MidCap debt facilities in July 2025, reducing interest expense by 98%.
• Customer Concentration: Sales from or through the top five health plan and PBM partners represented 78% of revenue. Two affiliates of The Cigna Group (Partner A and Partner B) accounted for 33% and 33% of revenue, respectively.

Guidance, Outlook, and Risks

• Outlook: Management expects to continue investing in R&D and sales to support growth. The company anticipates seasonality with higher sales closures in Q2 and Q3 aligning with benefits enrollment schedules.
• Strategic Focus: The company is expanding its GLP-1 Care Tracks and recently announced the capability to prescribe GLP-1 therapies and other anti-obesity medications (AOMs) to support members.
• Material Weakness in Internal Controls: The company disclosed that its disclosure controls and procedures were not effective as of March 31, 2026, due to a material weakness in internal control over financial reporting. This relates to inadequate formalized processes for the financial close, review of financial information, and journal entries. Remediation efforts are underway, including hiring qualified personnel and enhancing technology infrastructure.
• Risks: Key risks include reliance on a limited number of channel partners (Cigna affiliates), regulatory changes regarding virtual care and AI, potential supply chain disruptions for medical devices, and the ability to maintain member engagement and clinical outcomes to satisfy performance guarantees.

Investor Verification Checklist

• Verify the progress of remediation efforts regarding the material weakness in internal controls and the timeline for achieving effective internal controls over financial reporting.
• Monitor the renewal rates and contract terms with The Cigna Group affiliates, which represent a significant portion of revenue and accounts receivable.
• Assess the impact of tariffs and supply chain costs on hardware margins, as device manufacturing relies on international suppliers (China, Dominican Republic).
• Review the adoption rates and revenue contribution of the new GLP-1 prescribing capabilities and Care Tracks.
• Track member engagement metrics and clinical outcomes to ensure compliance with performance-based repayment clauses in customer contracts.